 AUSTIN, Texas, May 28, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA cfDNA testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant RevealsTM true test performance and the differences between tumor-informed and tumor-naive molecular residual disease MRD tests. Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, Docket No.6:21-cv-00540, alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act. 